Compare · BTAI vs TNYA
BTAI vs TNYA
Side-by-side comparison of BioXcel Therapeutics Inc. (BTAI) and Tenaya Therapeutics Inc. (TNYA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. BTAI focuses on Biotechnology: Pharmaceutical Preparations, while TNYA focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- TNYA is the larger of the two at $154.1M, about 4.7x BTAI ($33.0M).
- Over the past year, BTAI is down 46.0% and TNYA is up 2.2% - TNYA leads by 48.2 points.
- TNYA has been more active in the news (14 items in the past 4 weeks vs 6 for BTAI).
- BTAI has more recent analyst coverage (12 ratings vs 7 for TNYA).
- Company
- BioXcel Therapeutics Inc.
- Tenaya Therapeutics Inc.
- Price
- $1.07-3.59%
- $0.71+2.29%
- Market cap
- $33.0M
- $154.1M
- 1M return
- -11.16%
- -29.28%
- 1Y return
- -45.98%
- +2.21%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2021
- News (4w)
- 6
- 14
- Recent ratings
- 12
- 7
BioXcel Therapeutics Inc.
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutics, Inc. has a collaboration with collaboration with the VA Connecticut Healthcare System and the Yale University Medical School for patients suffering from post-traumatic stress disorder related to alcohol and substance abuse disorder. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Tenaya Therapeutics Inc.
Tenaya Therapeutics, Inc. develops therapeutics for heart failure. It offers cellular regeneration platform, that enables in vivo reprogramming of cardiac fibroblasts into cardio myocytes by delivering proprietary transcription factors; gene therapy platform, that enables the targeted delivery of a payload to cardiac fibroblasts; and precision medicine platform, which provides personalized medicine approach to treat heart disease. The company was incorporated in 2016 and is based in South San Francisco, California.
Latest BTAI
- BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting
- Chief Scientific Officer Yocca Frank converted options into 17,500 shares and sold $7,427 worth of shares (6,845 units at $1.08) as part of a pre-agreed trading plan, increasing direct ownership by 69% to 26,175 units (SEC Form 4)
- Officer Rodriguez Javier converted options into 17,500 shares and sold $7,111 worth of shares (6,560 units at $1.08) as part of a pre-agreed trading plan, increasing direct ownership by 69% to 26,803 units (SEC Form 4)
- Chief Financial Officer Steinhart Richard I converted options into 17,500 shares and sold $7,427 worth of shares (6,845 units at $1.08) as part of a pre-agreed trading plan, increasing direct ownership by 68% to 26,300 units (SEC Form 4)
- CEO and President Mehta Vimal converted options into 49,758 shares and sold $21,108 worth of shares (19,419 units at $1.09) as part of a pre-agreed trading plan, increasing direct ownership by 77% to 69,598 units (SEC Form 4)
- SEC Form 144 filed by BioXcel Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by BioXcel Therapeutics Inc.
- BioXcel Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by BioXcel Therapeutics Inc.
- BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
Latest TNYA
- Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms
- Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026
- SEC Form 4 filed by Director Williams R Sanders
- SEC Form 4 filed by Director Walsh Jeffrey T.
- SEC Form 4 filed by Director Stehman-Breen Catherine
- SEC Form 4 filed by Director Srivastava Deepak
- SEC Form 4 filed by Director Parschauer Karah Herdman
- SEC Form 4 filed by Director Lee June
- SEC Form 4 filed by Director Burroughs Amy L.
- Tenaya Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders